Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesEW +2.78%98 EV-to-OCF is 35.31 as of Aug. 03, 2026, which is 13% below its 10-year median of 40.69. GuruFocus rates EW with a GF Score™ of 98/100 and a GF Value™ of $94.28 (Fairly Valued). The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 86.64% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Edwards Lifesciences's Enterprise Value is $47,967 Mil.
Edwards Lifesciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $1,359 Mil. Therefore, Edwards Lifesciences's EV-to-OCF for today is 35.31.
The historical rank and industry rank for Edwards Lifesciences's EV-to-OCF or its related term are showing as below:
EW'
s EV-to-OCF Range Over the Past 10 Years
Min: 24.63 Med: 40.69 Max: 104.26
Current: 35.31
During the past 13 years, the highest EV-to-OCF of Edwards Lifesciences was 104.26. The lowest was 24.63. And the median was 40.69.
EW's EV-to-OCF is ranked worse than 86.64% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.89
vs EW: 35.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Edwards Lifesciences's PE Ratio (TTM) for today is calculated as:
Edwards Lifesciences's share price for today is $88.46.
Edwards Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Edwards Lifesciences EV-to-OCF Related Terms
Edwards Lifesciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's EV-to-OCF falls into.
Edwards Lifesciences's current Enterprise Value is $47,967 Mil.
Edwards Lifesciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,359 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a EV-to-OCF of 35.31 as of Aug. 03, 2026. This is 13% below median its historical median of 40.69. Over the past decade, Edwards Lifesciences' EV-to-OCF has ranged from 24.63 to 104.26. According to the industry distribution chart, Edwards Lifesciences ranks #739 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is Edwards Lifesciences' EV-to-OCF too high?
Edwards Lifesciences' current EV-to-OCF of 35.31 is 13% below median its 10-year median of 40.69. Over the past 10 years, this metric has ranged from a low of 24.63 to a high of 104.26. The Medical Devices & Instruments industry median EV-to-OCF is 7.89. Edwards Lifesciences' value of 35.31 is 347.5% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #739 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EV-to-OCF compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #739 out of 853 companies for EV-to-OCF. This places Edwards Lifesciences in the lower half of its industry. The industry median EV-to-OCF is 7.89. Edwards Lifesciences' value of 35.31 is 347.5% above this benchmark. Historically, Edwards Lifesciences' own EV-to-OCF has ranged from 24.63 to 104.26 over the past decade. While the company's 10-year median is 40.69 vs. the industry median of 7.89, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current EV-to-OCF of 35.31 is 347.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current EV-to-OCF is 35.31, which is 13% below median its own 10-year median of 40.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $94.28, compared to a current price of $88.46 — trading 6.2% below its estimated fair value. The current EV-to-OCF is 35.31, which is 13% below median its 10-year median of 40.69 and 347.5% above the Medical Devices & Instruments industry median of 7.89. Edwards Lifesciences' overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current EV-to-OCF is 35.31 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $88.46 is trading 6.2% below its estimated GF Value™ of $94.28.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for EW:
EV-to-OCF: 35.31 (13% below median its 10-year median of 40.69)
GF Value™: $94.28 vs. price of $88.46 (6.2% below fair value)
Industry Position: 347.5% above the Medical Devices & Instruments median (#739 of 853)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
98GF Score
Get the complete analysis for EW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
